BioSpace News Archive

BioUtah, Utah’s trade association serving the state’s life sciences community, announced today an impressive line-up of speakers who will present at this year’s 2023 Mayer Brown Utah Life Sciences Summit, November 9 at the Salt Palace Convention Center, in Salt Lake City.

CervoMed Inc. announced an oral presentation by Dr. Niels Prins, Chief Executive Officer of the Brain Research Center in the Netherlands, at the 16th Clinical Trials in Alzheimer’s Disease conference highlighted the neflamapimod clinical development program, including the RewinD-LB Phase 2b study design and the supportive Phase 2a clinical data, for the treatment of patients with dementia with Lewy bodies.

Corcept Therapeutics Incorporated announced it will report third quarter financial results and provide a corporate update on November 1, 2023.

Regeneron Pharmaceuticals, Inc. will webcast management participation as follows.

Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Tuesday, October 31, 2023, before the opening of the U.S. financial markets.

Ligand Pharmaceuticals Incorporated will report third quarter 2023 financial results after the close of the U.S. financial markets on Wednesday, November 8, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT) today announced that it will release its financial results for the quarter ended September 30, 2023 after the market close on Tuesday, November 14 and will also host a conference call and webcast at 4:30 pm Eastern Time on November 14, 2023.

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the third quarter of 2023 after the market closes on Wednesday, November 8, 2023.

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical drug discovery and development, today reported financial results for its fourth quarter and fiscal 2023, ended August 31, 2023.

XORTX Therapeutics Inc. announces that further to its earlier press release, the special meeting of shareholders has been rescheduled to 10:00 a.m. on Friday, October 27, 2023.